COMMUNIQUÉS West-GlobeNewswire
-
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
30/01/2026 -
ALX Oncology Announces Pricing of Underwritten Offering
30/01/2026 -
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
30/01/2026 -
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
30/01/2026 -
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
30/01/2026 -
IO Biotech Provides Corporate Update
30/01/2026 -
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
30/01/2026 -
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/01/2026 -
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
30/01/2026 -
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy
30/01/2026 -
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
30/01/2026 -
PhenQ 2026: OTC appetite suppressant search analysis for phentermine alternatives
30/01/2026 -
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
30/01/2026 -
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
30/01/2026 -
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
30/01/2026 -
Vaxcyte Announces Pricing of $550 Million Public Offering
30/01/2026 -
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
30/01/2026 -
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
29/01/2026 -
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
29/01/2026
Pages